Y-3 for （）

Phase 1Small molecule

NNeurodawn Pharmaceutical Co., Ltd.

Y-3 for （） is one of 4 small molecule programs targeting Hepatic Insufficiency. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic InsufficiencyNot yet recruiting

Hepatic InsufficiencyPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Hepatic Insufficiency

#DrugCompanyPhaseTrials

INCB161734

Incyte

Phase 1

1 2

LY3537031

Eli Lilly

Phase 1

1 3

Ulonivirine

Merck & Co.

Phase 1

1 4

Y-3 for （）

NNeurodawn Pharmaceutical Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatic Insufficiency1 trial

Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects

Not yet recruiting·NNeurodawn Pharmaceutical Co., Ltd.·Phase 1·NCT07055412·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Y-3 for （）. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Y-3 for （） compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Y-3 for （）. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neurodawn Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNeurodawn Pharmaceutical Co., Ltd.

Y-3 for （）

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatic Insufficiency1 trial

References

Drug Info

Quick Facts

Related News